The effect of selective serotonin re‐uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.

British Journal of Clinical Pharmacology

Volumn 34, Issue 3, 1992, Pages 262-265

  Crewe, HK ^a   Lennard, MS ^a   Tucker, GT ^a   Woods, FR ^a   Haddock, RE ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 DEHYDROSPARTEINE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; CYTOCHROME P450 ISOENZYME; DESIPRAMINE; DRUG METABOLITE; FLUOXETINE; FLUVOXAMINE; LIDOCAINE; METOPROLOL; MEXILETINE; NORFLUOXETINE; PAROXETINE; PHENAZONE; QUINIDINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SPARTEINE; THIORIDAZINE;

ARTICLE; CONTROLLED STUDY; DONOR; DRUG METABOLISM; HUMAN; HUMAN TISSUE; LIVER MICROSOME; PRIORITY JOURNAL;

1-NAPHTHYLAMINE; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CITALOPRAM; COMPARATIVE STUDY; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FLUOXETINE; FLUVOXAMINE; HUMAN; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; PAROXETINE; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SPARTEINE;

EID: 0026787192     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1992.tb04134.x     Document Type: Article

References (17)

1. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in depressive illness
2. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes
3. Fluoxetine and norfluoxetine are potent inhibitors of P450IID6—the source of the sparteine/debrisoquine oxidation polymorphism
4. Extremely slow metabolisers of amitriptyline but normal metabolisers of imipramine and desipramine in an extensive metaboliser of sparteine, debrisoquine and mephenytoin
5. The effect of paroxetine and other specific 5‐HT re‐uptake inhibitors on cytochrome P450IID6 activity in human liver microsomes
6. Paroxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness
7. Metabolic pathways of paroxetine in animals and man and the comparative pharmacological properties of its metabolites
8. Sertraline, 1S,4S‐N‐methyl‐4‐(3,4‐dichlorophenyl)‐1,2,3,4‐tetrahydro‐1‐naphthylamine, a new uptake inhibitor with selectivity for serotonin
9. Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal
10. The P450 superfamily: update on new sequences, gene mapping and recommended nomenclature
11. 3H]GBR‐12935 binding proteins
12. Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs
13. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes
14. The relationship between paroxetine and sparteine oxidation polymorphism
15. Inhibition of desmethylimipramine 2‐hydroxylation by drugs in human liver microsomes
16. Fluoxetine‐induced tricyclic toxicity: extent and duration